- Report
- January 2024
- 200 Pages
Global
From €4802EUR$5,000USD£4,100GBP
- Report
- March 2024
- 145 Pages
Global
From €3745EUR$3,899USD£3,197GBP
- Report
- November 2023
- 139 Pages
Global
From €3059EUR$3,185USD£2,611GBP
€4370EUR$4,550USD£3,731GBP
- Report
- January 2024
- 395 Pages
Global
From €7203EUR$7,500USD£6,149GBP
- Drug Pipelines
- July 2019
- 345 Pages
Global
€21129EUR$22,000USD£18,038GBP
- Report
- March 2024
- 50 Pages
Global
From €2545EUR$2,650USD£2,173GBP
- Report
- September 2019
Global
From €5158EUR$5,370USD£4,403GBP
- Report
- January 2022
- 137 Pages
Global
From €4322EUR$4,500USD£3,690GBP
- Book
- July 2009
- 1116 Pages
Rufinamide is a medication used to treat seizures associated with Lennox-Gastaut syndrome, a rare form of epilepsy. It is classified as an anticonvulsant and works by decreasing the number of abnormal electrical signals in the brain. Rufinamide is typically used in combination with other anticonvulsants to control seizures. It is available in tablet and oral suspension form.
Rufinamide is a relatively new drug in the Central Nervous System (CNS) drugs market. It is used to treat a rare form of epilepsy, making it a niche drug. It is typically used in combination with other anticonvulsants, which can help to reduce the risk of side effects.
Several companies are involved in the Rufinamide market, including Eisai, Inc., Sun Pharmaceutical Industries Ltd., and Mylan N.V. These companies manufacture and distribute the drug in various countries around the world. Show Less Read more